Allergan
⚠️ Moderate Risk
FEI: 3005658769 • Marlow, Buckinghamshire • UNITED KINGDOM
FEI Number
3005658769
Location
Marlow, Buckinghamshire
Country
UNITED KINGDOMAddress
Marlow International, Parkway, Marlow, Buckinghamshire, United Kingdom
Moderate Risk
FDA Import Risk Assessment
This firm has a moderate history of FDA import refusals. Some attention may be warranted.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
NO LICENSE
The article is subject to refusal of admission under section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because it appears to be a biological product for which a biologics license is not in effect under the Public Health Service Act, Part F, Subpart 1-Biological Products, Section 351(a), and it is not the subject of an Investigational New Drug application that is in effect. Therefore, it appears to be a new drug under 201(p) of the FD&C Act that it is in violation of section 505(a) of the FD&C Act because it lacks a new drug approval and because it is misbranded under section 502(f)(1)of the FD&C Act because it fails to bear adequate directions for use
NO PMA
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the device appears to be a Class III device and does not appear to have in effect an approved application for premarket approval pursuant to Section 515 of the Act, or an exemption pursuant to Section 520(g)(1).
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
RX DEVICE
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a prescription device that appears to not feature a prescription device legend as required by 21 CFR 801.109.
NO ENGLISH
Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 12/12/2022 | 65QBY02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/8/2022 | 53YY99OTHER COSMETIC AND COSMETIC PRODUCTS, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 12/27/2019 | 65QBY02BOTOX | Division of Northern Border Imports (DNBI) | |
| 12/18/2018 | 65QAY02BOTOX | Division of Southeast Imports (DSEI) | |
| 11/21/2018 | 65QCL02BOTOX | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 11/9/2018 | 65QBY02BOTOX | Division of Southeast Imports (DSEI) | |
| 9/28/2018 | 79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE | Division of Southeast Imports (DSEI) | |
| 6/1/2018 | 65QDY02BOTOX | Division of Southeast Imports (DSEI) | |
| 5/21/2018 | 65QIY02BOTOX | Division of Southeast Imports (DSEI) | |
| 5/15/2018 | 65QDY02BOTOX | Division of Southeast Imports (DSEI) | |
| 4/25/2018 | 65QBR02BOTOX | Division of Southeast Imports (DSEI) | |
| 7/16/2015 | 79LMHIMPLANT, DERMAL, COLLAGEN FOR AESTHETIC USE | Cincinnati District Office (CIN-DO) | |
| 4/24/2015 | 66VBJ99MISCELLANEOUS PATENT MEDICINES, ETC. | Los Angeles District Office (LOS-DO) | |
| 4/24/2015 | 65QAK02BOTOX | Los Angeles District Office (LOS-DO) |
Frequently Asked Questions
What is Allergan's FDA import refusal history?
Allergan (FEI: 3005658769) has 14 FDA import refusal record(s) in our database, spanning from 4/24/2015 to 12/12/2022.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Allergan's FEI number is 3005658769.
What types of violations has Allergan received?
Allergan has been cited for 8 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Allergan come from?
All FDA import refusal data for Allergan is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.